Immatics
Bristol Myers Squibb Terminates Cell Therapy Collaborations with Immatics and Century Therapeutics
Bristol Myers Squibb, Immatics, Century Therapeutics, cell therapy, portfolio review, collaboration termination
Bristol Myers Squibb Terminates Cell Therapy Collaborations with Immatics and Century Therapeutics Amid Cost-Cutting Measures
Bristol Myers Squibb, Immatics, Century Therapeutics, cell therapy, cost-cutting, strategic productivity initiative, portfolio prioritization
Immatics Advances Melanoma T-Cell Therapy into Late-Stage Clinical Trials
Immatics, melanoma, T-cell therapy, ACTengine IMA203, late-stage clinical trials, SUPRAME Phase 3 trial
Bristol Myers Terminates Partnership with Immatics on Bispecific Cancer Drug After $150M Investment
Bristol Myers Squibb, Immatics, bispecific cancer drug, partnership termination, $150M investment